Summary
The pharmacokinetics of etoposide following a new method of administration was determined. Undiluted etoposide was given at a dose of 30 mg/kg as part an intensified conditioning regimen prior to bone marrow transplantation. A terminal half-life of 3.4±0.7 h and a volume of distribution of 15.4±9.61 were found (n=8); the AUC was 764±302 μg h ml−1. As compared with those obtained in other pharmacokinetic studies using etoposide diluted in normal saline, our data reflect full systemic bioavailability and unaltered pharmacokinetics. The application of undiluted etoposide makes the therapy easier and less time-consuming and avoids a high fluid volume and a high saline load.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Blume KG, Forman SJ, O'Donnell MR, Doroshow JH, Krance RA, Nademanee AP, Snyder DS, Schmidt GM, Fahey JL, Metter GE (1987) Total body irradiation and high-dose etoposide: a new preparatory regimen for bone marrow transplantation in patients with advanced hematologic malignancies [erratum published in Blood 69 (6): 1789]. Blood 69: 1015–1020
Creger RJ, Fox RM, Lazarus HM (1990) Infusion of high doses of undiluted etoposide through central venous catheters during preparation for bone marrow transplantation. Cancer Invest 8: 13–16
Hande KR, Wedlund PJ, Noone RM, Wilkinson GR, Greco FA, Wolff SN (1984) Pharmacokinetics of high-dose etoposide (VP-16-213) administered to cancer patients. Cancer Res 44: 379–382
Heinzel G, Hammer R, Wolf M (1977) Modellentwicklung in der Pharmakokinetic. Drug Res 27: 904–911
Joel SP, Maclean MC, Slevin ML (1989) The stability of the intravenous preparation of etoposide in isotonic fluids (abstract). Proc Am Assoc Cancer Res 30: 244
Lazarus HM, Creger RJ, Diaz D (1986) Simple method for the administration of high-dose etoposide during autologous bone marrow transplantation. Cancer Treat Rep 70: 819–820
Newman EM, Doroshow JH, Forman SJ, Blume KG (1988) Pharmacokinetics of high-dose etoposide. Clin Pharmacol Ther 43: 561–564
Schmitz N, Gassmann W, Rister M, Johannson W, Suttorp M, Brix F, Holthuis JJ, Heit W, Hertenstein B, Schaub J (1988) Fractionated total body irradiation and high-dose VP 16-213 followed by allogeneic bone marrow transplantation in advanced leukemias. Blood 72: 1567–1573
Slevin ML, Clark PI, Joel SP, Malik S, Osborne RJ, Gregory WM, Lowe DG, Reznek RH, Wrigley PF (1989) A randomized trial to evaluate the effect ofschedule on the activity of etoposide in small-cell lung cancer. J Clin Oncol 7: 1333–1340
Zander AR, Culbert S, Jagannath S, Spitzer G, Keating M, Larry N, Cockerill K, Hester J, Horwitz L, Vellekoop L (1987) High dose cyclophosphamide, BCNU, and VP-16 (CBV) as a conditioning regimen for allogeneic bone marrow transplantation for patients with acute leukemia. Cancer 59: 1083–1086
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ehninger, G., Proksch, B., Schmidt, H. et al. Unaltered pharmacokinetics after the administration of high-dose etoposide without prior dilution. Cancer Chemother. Pharmacol. 28, 214–216 (1991). https://doi.org/10.1007/BF00685512
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00685512